Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
AUTX-703 in Relapsing acute myeloid leukemia: NCT06846606 Clinical Landscape Report 2026
16 October 2026
NCT06846606 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Zabalafin in Eczema: NCT06855745 Clinical Landscape Report 2026
16 October 2026
NCT06855745 clinical landscape for Eczema: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Abatacept in Acute Myeloid Leukemia: NCT06859424 Clinical Landscape Report 2026
16 October 2026
NCT06859424 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06852222 Clinical Landscape Report 2026
16 October 2026
NCT06852222 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Remibrutinib in Multiple sclerosis relapse: NCT06846281 Clinical Landscape Report 2026
16 October 2026
NCT06846281 clinical landscape for Multiple sclerosis relapse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Donor-derived Anti-leukemia Cytotoxic T Lymphocytes(Fondazione IRCCS Policlinico San Matteo) in Acute Myeloid Leukemia: NCT06865352 Clinical Landscape Report 2026
16 October 2026
NCT06865352 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SFA-002 in Plaque psoriasis: NCT06863493 Clinical Landscape Report 2026
16 October 2026
NCT06863493 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ublituximab in Multiple Sclerosis, Relapsing-Remitting: NCT06864936 Clinical Landscape Report 2026
16 October 2026
NCT06864936 clinical landscape for Multiple Sclerosis, Relapsing-Remitting: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Lutikizumab in Arthritis, Psoriatic: NCT06865105 Clinical Landscape Report 2026
16 October 2026
NCT06865105 clinical landscape for Arthritis, Psoriatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tirzepatide in Salivary Gland Adenoma, Pleomorphic: NCT06864026 Clinical Landscape Report 2026
16 October 2026
NCT06864026 clinical landscape for Salivary Gland Adenoma, Pleomorphic: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Ofatumumab in Multiple sclerosis relapse: NCT06869785 Clinical Landscape Report 2026
16 October 2026
NCT06869785 clinical landscape for Multiple sclerosis relapse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Afimkibart in Dermatitis, Atopic: NCT06863961 Clinical Landscape Report 2026
16 October 2026
NCT06863961 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.